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Abstract
Background and Objectives Lactobacillus plantarum
strains are known to exhibit an antimicrobial property
against bacteria and fungi. In the present investigation,
AMPs LR14, antimicrobial peptides produced by L. plan-
tarum strain LR/14, were tested against a protozoan sys-
tem, Plasmodium falciparum and its non-toxic nature was
envisaged on a mammalian system.
Methods Human erythrocytes infected with chloroquine-
sensitive and -resistant strains of P. falciparum were trea-
ted with purified AMPs LR14. The loss in cell viability was
assessed by monitoring the incorporation of [3H]-hypo-
xanthine in the nucleic acid of the parasite. The hemolytic
activity of AMPs LR14 was monitored at different con-
centrations and the investigations into the in vivo toxicity
of AMPs LR14 were carried out on a mammalian system
(Wistar rat). The level of toxicity in the tissues was visu-
alized by histopathological studies conducted on the liver
and kidney of the test and control rats. A study was also
undertaken to see the production of antibodies in an animal
(rabbit) after it was immunized with AMPs LR14.
Results A loss in cell viability was observed in both test
strains of P. falciparum. However, the dose required for
inhibition of the chloroquine-resistant strain was *2 times
the dose required for the chloroquine-sensitive strain. At
these concentrations, no hemolysis of human erythrocytes
was observed. The studies conducted on in vivo toxicity of
AMPs LR14 suggest that the lethal dose (LD50) is beyond
1,000 mg/kg body weight, suggesting its safe use against
microbes and protozoans. Antibodies were also not detec-
ted against these peptides, indicating a non-immunogenic
nature.
Conclusion The data indicate that AMPs LR14 are non-
toxic, potent anti-plasmodial peptides causing growth
inhibition of P. falciparum without causing hemolysis.
These results pave the way for the development of bioac-
tive peptides as therapeutics.
Key Points
Lactobacillus plantarum strains are not known to
exhibit anti-protozoan activity to the best of our
knowledge. In the present investigation, the anti-
plasmodial activity of AMPs, LR14 antimicrobial
peptides produced by L. plantarum strain LR/14, was
demonstrated on Plasmodium falciparum.
The lethal effect occurred only on the protozoan
parasites and the erythrocytes remained unaffected
by the peptide action.
Histopathological findings suggest that the extent of
damage was negligible at the tissue level.
1 Introduction
Malaria, caused by a protozoan parasite, is considered one
of the most important endemic diseases afflicting
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subtropical countries and is the ninth most significant cause
of mortality globally [1, 2]. Of the four human malaria
parasite species, Plasmodium falciparum has been rated as
the most malignant and causative agent of cerebral malaria
[3]. During the last few decades, there has been an emer-
gence of clinical resistance to first-line treatment of anti-
malarial drugs. The widespread resistance of P. falciparum
to chloroquine has rendered the drug ineffective against the
most dangerous Plasmodium strain. Moreover, chloroquine
resistance is associated with cross-resistance to other
quinoline drugs, such as quinine and amodiaquine [4]. In
the fight against resistance, artemisinin-based combination
therapies (ACT) and its derivatives have provided a respite
[5]. However, the search for novel lead compounds that can
be developed as a cure for malaria is still active. One such
group of compounds are peptides produced naturally or
which are synthetic in nature [2, 6].
For its successful existence and to protect itself from
other pathogens, bacteria synthesize antimicrobial peptides
(AMPs). These AMPs are ribosomally synthesized and are
generally known as bacteriocins [7]. They form an innate
part of the lactic acid bacteria defense system [8, 9]. These
peptides have remained effective weapons since times
immemorial against bacteria and fungi. It is generally
believed that resistance can be developed in microorgan-
isms in response to a therapeutic molecule/compound;
however, there are very few studies reporting the devel-
opment of resistance against bacteriocins/AMPs. The rea-
sons for this are that they are highly selective against the
negatively charged bacterial membrane versus the zwit-
terionic mammalian membranes of a human host, and,
secondly, the non-specificity in targeting is unlikely to
evoke resistance [10]. The majority of reports suggest an
association of these bacteriocins with the killing of path-
ogenic Gram-positive and Gram-negative bacteria as well
as fungi [11–13]. Considering the inhibitory spectrum of
these AMPs, they are turning out to be powerful agents for
targeting bacteria, fungi, and parasites, and there may be
other targets that they can be tested upon [6]. For any such
application, it is mandatory to test and provide information
on toxicity/ill effects of the compound under consideration.
While humans are the endpoint beneficiary for all such
applications, due to ethical reasons it is not possible to
conduct toxicity testing directly on human beings; hence,
toxicity tests on animals are conducted prior to human
clinical investigations as part of the non-clinical laboratory
tests of pharmaceuticals [14].
The present study aimed to explore the possibility of
unravelling a safe and therapeutic alternative in the form of
AMPs. Previously, we purified and described a two-peptide
bacteriocin from Lactobacillus plantarum strain LR/14
exhibiting a wide antibacterial spectrum [15, 16]. Further,
we have shown that the strain LR/14 produces additional
peptides, AMPs LR14 [17]. The AMPs LR14 mixture was
therefore purified by three-phase partitioning and gel-fil-
tration chromatography; it appeared to contain four AMPs
with a molecular mass less than 1 kDa and to be devoid of
plantaricins LR14-a and -b (unpublished data). These
peptides show antimicrobial effect against some patho-
genic bacteria and fungi [18] and also probable insecticidal
properties [17].
These peptides, AMPs LR14, were investigated for their
efficacy against a human pathogen, P. falciparum. The
study clearly demonstrates that the growth of the parasite
was inhibited in a dose-dependent manner with almost
negligible hemolytic activity. This is a preliminary study,
but identifies an important lead that can be pursued further.
Furthermore, we have conducted in vivo toxicity studies to
evaluate its maximum tolerable dose and histological
analysis of some tissues to suggest safe administration of
AMPs LR14 if it is required to be tested in humans. We
have also studied the immunogenic response of AMPs
LR14 in a mammalian system.
2 Methods
2.1 Source of Antimicrobial Peptides (AMPs) LR14
L. plantarum strain LR/14 was maintained on MRS agar
medium (de Man-Rogosa-Sharpe medium, HiMedia,
Mumbai, India). The culture was raised at 37 C under
static conditions for 24 h. The culture supernatant was
obtained by centrifugation at 6,000 9 g at 4 C for 10 min
and served as the source of crude AMPs LR14. For puri-
fication, proteins were precipitated by three-phase parti-
tioning using ammonium sulfate and tertiary butanol. The
protein precipitate appeared as an interfacial layer which
was separated, washed a few times, and dissolved in sterile
distilled water. This was further subjected to gel-filtration
chromatography using Sephadex G-25 desalting columns
(GE-Healthcare Bio-Sciences, USA). All chemicals used
were of analytical grade, and all media used were pur-
chased from HiMedia (Mumbai, India).
2.2 Quantification of AMPs LR14
Concentration of AMPs LR14 was determined using a
BCA (bicinchoninic acid) protein assay kit, as recom-
mended by the supplier (Sigma-Aldrich, USA). Antimi-
crobial action was assayed in terms of both qualitative
[agar well diffusion assay (AWDA)] and quantitative (AU/
mL) methods [17, 18]. One activity unit (AU) was defined
as the reciprocal of the amount of bacteriocin that inhibited
the growth of the indicator organism by 50 %, when
compared with the untreated control.
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AWDA was performed by overlaying soft nutrient agar
(0.8 %) seeded with indicator strain (*1 9 106 cfu/mL)
Micrococcus luteus on the NB base agar plate. The wells
cut out (6.0 mm diameter) on such plates were filled
(100 lL) with the AMPs. Halo produced after overnight
incubation was used as an indicator of growth inhibition.
The antimicrobial ability of the peptides (AMPs LR14) was
quantified in terms of activity units (AU/mL). For this,
150 lL of NB, 50 lL of AMPs LR14 at twofold serial
dilutions, and 50 lL of the culture of the indicator organ-
ism were mixed in different wells of a microtiter plate.
These plates were incubated for 6 h at 37 C and the
growth was measured spectrophotometrically at 630 nm
using a microtiter plate reader (Bio-Rad, USA) and com-
pared with an untreated sample.
2.3 Drug Dilutions
Stock solutions of AMPs LR14 and chloroquine diphos-
phate (10 mg/mL) were prepared in water (milli-Q grade).
All stocks were then further diluted with incomplete
RPMI-1640 (without serum) to achieve the required
concentrations.
2.4 In Vitro Culture of Plasmodium falciparum
The strains of P. falciparum used in the study, 3D7
(chloroquine sensitive) and RKL19 (chloroquine resistant),
were obtained from the National Institute of Malaria
Research (NIMR), New Delhi, India. The strains were
maintained by a modified method of Desjardins et al. [19]
by serial passages in human erythrocytes cultured at 4 %
hematocrit in RPMI-1640 medium supplemented with
10 % human serum and incubated at 37 C under the
atmosphere of mixed gases (5 % CO2, 5 % O2, and 90 %
N2) in a plastic chamber. Heparinized whole O
? blood was
collected from the Rotary Blood Bank, New Delhi, India,
and red blood cells (RBCs) were separated under sterile
conditions by centrifugation to remove serum and buffy
coat. The levels of parasitemia were routinely monitored
on blood smear with 5 % Giemsa-azure type B stain in
phosphate buffer (20 mM, pH 7.2). For each experiment,
samples of the stock culture were further diluted in culture
medium upto 2 % hematocrit and 1 % parasitemia.
2.5 Evaluation of Anti-Plasmodial Activity of AMPs
LR14
Briefly, different concentrations derived from twofold
serial dilution of AMPs LR14 (0.6–42 lg/mL) were added
to P. falciparum-infected erythrocyte suspension (2 % final
hematocrit and 1 % parasitemia) in a 96-well tissue culture
plate along with an untreated control. In another set,
different concentrations of chloroquine diphosphate were
added to infected erythrocyte suspension as the positive
control. Negative control included media incubated with
infected RBCs.
After 24 h of incubation at 37 C, 20 lL of 0.2 lCi/well
of [3H]-hypoxanthine (American Radiolabeled Chemicals,
Inc., specific activity 25 Ci/mmol) was added to each well
containing unsynchronized parasite culture. After 18 h of
incubation, the cells were harvested onto a glass-fibre filter
paper using a Skatron Semi-automated cell harvester [19].
The paper discs were placed in a 5 mL scintillation cocktail
that consisted of (1 L) 0.1 g POPOP (1,4, bis 2-5 phenyl
oxazolyl benzene), 4 g PPO (2-5 diphenyl oxazole),
300 mL ethanol, and 700 mL toluene and stirred overnight.
[3H]-hypoxanthine incorporation in nucleic acid was
measured in a liquid scintillation b-counter (Model: Tri-
Carb 2900 TR, Perkin Elmer, USA). The cell viability was
calculated by comparison with control, which consisted of
complete medium as a substitute for the test molecule. The
concentration of drug producing 50 % inhibition (IC50)
values were determined by plotting the drug concentration
versus the percentage cell viability of the parasite after
24 h of incubation. All data points were collected in trip-
licate for each independently conducted experiment.
2.6 Assessment of Hemolytic Activity
Hemolysis was measured in AMPs LR14-treated sets of
cultured infected and uninfected erythrocytes by measuring
the absorbance of hemoglobin at 405 nm [20]. Heparinized
fresh blood was rinsed in phosphate buffered saline (PBS)
(by centrifugation at 200 9 g for 2 min) and resuspended
in PBS at 4 % hematocrit. Briefly, increasing concentra-
tions of AMPs LR14 were added to P. falciparum-infected
(2 % hematocrit and 1 % parasitemia) and -uninfected
erythrocytes (2 % hematocrit) in a 96-well plate for 42 h at
37 C. After incubation, the plate was spun down briefly
and absorbance of supernatant was read at 405 nm. Mixing
the erythrocytes with 1 % Triton-X 100 (for 100 %
hemolysis) and PBS alone (for baseline values) served as
positive and negative controls, respectively. Hemolytic
activity data were obtained from at least two independent
experiments.
2.7 Evaluation of In-Vivo Toxicity of AMPs LR14
on a Mammalian System
An acute oral toxicity test of AMPs LR14 on Wistar rats
was carried out at the Shriram Institute for Industrial
Research, Delhi, India. The studies were conducted in
compliance with Good Laboratory Practices (GLP) in
accordance with the OECD guidelines for testing of
chemicals for non-clinical laboratory studies.
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2.7.1 Experimental Design
A batch consisting of female Wistar rats (n = 5 per
group per dose) (Rattus rattus albanicus), each weighing
160–180 g, were used for each test with different con-
centrations of AMPs LR14. Initially an acclimatization
period of 5 days was given to the animals. The animals
were administered with a single dose of the test sub-
stance (AMPs LR14). One control group with vehicle,
i.e., normal saline, was also included in the plan of
work.
2.7.2 Method and Frequency of Administration
The animals were fasted overnight prior to dosing and
for 4 h after dosing. A batch (n = 5) was administered
with a single dose of AMPs LR14 solution orally at a
level of 50 mg/kg with the help of a canula attached to
the syringe. One control group was administered with the
vehicle, i.e., normal saline. Similarly, second, third, and
fourth doses of 300, 1,000, and 2,000 mg/kg, respec-
tively, were given to different batches of each group.
The test compound (AMPs LR14) was administered only
once to the test groups, and the animals were monitored
regularly for 14 days. Observations were made at least
once during the first 30 min, with special attention dur-
ing first 4 h on the day of dosing and daily thereafter for
a total of 14 days or until any adverse signs were
observed. Body weights were recorded prior to dosing
and weekly thereafter. All gross visible signs and
symptoms were also recorded.
2.7.3 Histopathological Analysis
Representative samples of the liver and kidney were
removed from the control and AMPs LR14 (1,000 mg/
kg) administered group of animals. The formalin-pre-
served tissue sections were processed as follows: (1)
fixation in 10 % neutral buffered formalin for 1 h, twice;
(2) dehydration in graded series of alcohol (70 % for
30 min, 90 % for 1 h, and two cycles of 100 % for 1 h
each); (3) dehydration again with xylene for 1.5 h, twice;
and (4) impregnated in molten wax at 65 C for 2.5 h
with two changes. The processed tissues were embedded
in paraffin and sectioned (4 l thickness) and dried on a
70 C hot plate for 30 min. The tissues were stained
using hematoxylin and eosin (H&E) stains. The stained
tissues were dehydrated with 70 % ethanol followed by
90 % ethanol, placed in two changes of 100 % ethanol
for 3 min each, and cleaned with two changes of xylene
(3 min each). The morphological changes were moni-
tored through a bright-field microscope (Leica TP1020,
Japan).
2.8 Studies on Generation of Immune Response
of AMPs LR14 in a Rabbit
A purified preparation of the peptide (200 lg/mL) was
used to immunize a rabbit, followed by the booster doses
(100 lg/mL) administered at an interval of 4 weeks. AMPs
LR14 as an antigen was injected subcutaneously and the
rabbit was bled after 4 months. Blood collected from the
animal was subjected to ELISA in order to detect the for-
mation of antibodies. Different dilutions (10 ng/mL,
100 ng/mL, 1 lg/mL, 10 lg/mL) of the antigen (purified
AMPs LR14) were added to a microtiter plate and kept for
incubation at 4 C overnight. The plate was washed with
0.01 M phosphate buffer pH 7.2. Casein was added to all
the wells and incubated at room temperature for 1 h.
Casein was removed from the wells and washed with
0.01 M PBS. The plate was tapped gently on a blotting
sheet.
Next, primary antibodies were added in different dilu-
tions comprising 1/10, 1/100, 1/500, 1/1,000, 1/2,000,
1/5,000, and 1/10,000. In one set, 1/10 pre-bled antiserum
was taken as the control. Washing was done again with
PBS three times and the plate was tapped gently every
time. Further, secondary antibodies [goat anti-rabbit IgG
and horse radish peroxidase (HRP) conjugate] were added
and the plates were incubated for 1 h at 37 C. This was
followed by three rounds of washing with PBS. The sub-
strate o-Phenylenediamine (OPD) at a concentration of
10 mg/mL was added to each well and plate was incubated
at room temperature for 30 min. Absorbance was read at
490 nm.
2.9 Statistical Analysis
The in vitro antiplasmodial experiments were conducted in
triplicate and the results represent the mean of two inde-
pendent experiments. The in vivo toxicity test was per-
formed for n = 5 per group of rats/dose per batch.
Parameters such as body weight changes were tabulated
and analyzed by Student’s t test.
3 Results
3.1 Quantification of AMPs LR14
The AMPs LR14 are a mixture of four peptides, and all the
peptides have molecular masses \1 kDa. These peptides
show considerable antimicrobial activity against the indi-
cator strain, M. luteus. The antimicrobial activity and
protein concentration of the four peptides are as follows:
peptide 1—12,500 AU/mL (500 lg/mL); peptide 2—
25,000 AU/mL (450 lg/mL); peptide 3—25,000 AU/mL
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(700 lg/mL); and peptide 4—12,500 AU/mL (700 lg/
mL). These peptides are different from other bacteriocins
known in the database as well as plantaricin LR14-a and -
b. Moreover, the retention time of any of these peptides
(AMPs LR14) did not match with plantaricins LR14-a and
-b, as confirmed by the high-performance liquid chroma-
tography (HPLC) chromatogram [17].
These peptides have been characterized in terms of their
heat and pH stability. They are tolerant to extremes of
temperature ranging from boiling to freezing at -20 C.
They are able to retain their activity in a wide range of pH
values (pH 2–10), and are susceptible to proteolytic
cleavage, which confirms their proteinaceous nature.
3.2 Evaluation of Anti-Plasmodial Activity of AMPs
LR14
P. falciparum takes up hypoxanthine as part of its purine
salvage pathway and its incorporation is a measure of
growth and viability of the parasite. Thus, the viability of
the parasite can be monitored by the extent of incorporation
of [3H] hypoxanthine. As described in Sect. 2, the infected
erythrocytes incubated with different concentrations of
AMPs LR14 along with [3H] hypoxanthine showed a dose-
dependent decline in the radioactive counts, reflecting the
effect on the viability of the parasite.
Different concentrations of AMPs LR14 ranging from 0.6
to 42 lg/mL showed inhibition in the range of 1–99 % in
comparison with an untreated control (considered as 100 %
viable). From the results obtained, IC50 was achieved in the
chloroquine-sensitive strain (3D7) at 1.6 lg/mL and the
chloroquine-resistant strain (RKL19) at 2.85 lg/mL of
AMPs LR14. In comparison, the IC50 level of chloroquine
(positive control) was 17.6 ng/mL for the chloroquine-sen-
sitive strain (3D7) and 100 ng/mL for the chloroquine-
resistant strain (RKL19). No hypoxanthine uptake could be
detected beyond the maximum tested dose of 42 lg/mL,
where 99 % inhibition was observed. Figure 1 depicts the
percentage cell viability at different concentrations of AMPs
LR14 used, in comparison to the control.
3.3 Assessment of Hemolytic Activity
In order to demonstrate that the anti-plasmodial activity of
AMPs LR14 was not due to lysis of erythrocytes, hemo-
lysis of infected and uninfected cells in response to AMPs
LR14 treatment was also investigated. No hemolysis was
observed in uninfected erythrocytes at different concen-
trations tested. However, in infected erythrocytes treated at
100 lg/mL, hemolysis to the level of about 1 % was
observed (Table 1). There was no hemolysis even at 50 lg/
mL, suggesting that the anti-plasmodial effect (as described
above) was independent of any hemolytic activity.
3.4 In Vivo Toxicity Test of AMPs LR14
on a Mammalian System
If these AMPs are to be developed as a therapeutic molecule, it
is important to study their toxicity. Therefore, we conducted
an in vivo toxicity test on a mammalian system comprising
Wistar rats. For this, the rats were administered with a single
oral dose of different concentrations of purified AMPs LR14.
All experimental animals (those treated and controls) were
observed for 14 days. During this period, there was no sig-
nificant difference in the body weights of untreated and treated
animals at some of the doses of AMPs LR14, such as 50, 300,
and 1,000 mg/kg (p \ 0.5). However, the rats fed with
2,000 mg/kg AMPs LR14 did not survive beyond 1 day, so
their weights were not considered (Table 3).
The results obtained after conducting the test on rats
provided an insight that under the given conditions no
treatment-related toxic signs and symptoms/mortality were
observed at the tested concentrations of 50 and 300 mg/kg.
On further increasing the AMPs LR14 concentration to
1,000 mg/kg, shivering in the animals was observed after
dosing, which subsided within 24 h and had no adverse
effect thereafter. Therefore, no mortality was observed at
this dose. However, on further increasing the dose con-
centration to 2,000 mg/kg, symptoms such as ruffled fur,
shivering, and ataxia were noticed in the tested group and
the animals died within 4 h after dosing (Tables 2, 3).
From these results, the lethal dose (LD50) value of AMPs
LR14 can be hypothesized to lie between 1,000 and
2,000 mg/kg.
Fig. 1 Effect of antimicrobial peptides (AMPs LR14) on the growth
of Plasmodium falciparum: P. falciparum-infected erythrocytes (2 %
final hematocrit and 1 % parasitemia) were incubated for 24 h at
37 C in the presence of different dosages of AMPs LR14. The
concentration of drug producing 50 % inhibition was assessed by
measuring the [3H] incorporation into nucleic acid of P. falciparum
cells. Experiments were performed with two strains of P. falciparum:
a chloroquine-resistant strain (RKL19) and a chloroquine-sensitive
strain (3D7). The mean value ± standard deviation is indicated for
each group and values are representative of three independent
experiments. AMPs antimicrobial peptides, CQ chloroquine
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Since some visible observations were recorded in the
rats treated at 1,000 mg/kg AMPs LR14, the histopathol-
ogical studies were carried out for that group of treated
animals. The microscopic findings suggest that the kidney
of the test rats showed a glomerulus with normal size and
cellularity. The malpighian tubules were also found to be
within normal limits. However, there was mild inflamma-
tion around the portal triad in the liver of the test rats in
comparison to their respective controls (Fig. 2).
3.5 Studies on Generation of Immune Response
Against AMPs LR14
Attempts were made to raise antibodies against AMPs
LR14 in a rabbit. However, no antibodies could be detec-
ted, suggesting that the peptides were not immunogenic.
4 Discussion
In the present investigation, the in vitro anti-plasmodial
activity of AMPs LR14 against chloroquine-sensitive and -
resistant strains was demonstrated. The erythrocytic phase
is the most important phase in the life cycle of the parasite,
when it invades the RBCs of the host and forms an acidic
compartment in the lysosome known as the digestive
vacuole (DV). The parasite grows in the RBCs and feeds
on the hemoglobin of the host cytosol. The parasite accu-
mulates the hemoglobin in the DV and degrades it into its
component peptides and heme to form a crystalline poly-
mer hemozoin. Chloroquine works on the fact that the
uncharged chloroquine species enters the DV and binds to
the hematin, thus preventing its addition into the hemozoin
formation. Hematin is a toxic byproduct released during
proteolysis of hemoglobin which hinders the detoxification
process of the parasite. However, in a chloroquine-resistant
strain, mutations in a chloroquine transporter protein do not
allow the exit of positively charged chloroquine from the
vacuole, thus resulting in a net decrease in chloroquine
levels inside the DV [21].
The mechanism by which AMPs LR14 show anti-plas-
modial activity on asexual erythrocytic stages is unclear.
However, it can be hypothesized that differences in the
membrane composition, i.e., interaction of the positively
charged peptides with the negatively charged surface
molecules of the parasites, might play a significant role in
killing of the host cells. Also, changes in the functional and
structural characteristics of infected erythrocytes has also
been reported by various workers when the plasmodium-
infected cells are targeted with cationic peptides [6]. These
modifications include a marked increase in erythrocyte
membrane fluidity, alteration of the host cell’s lipid, fatty
acid, protein composition, and phospholipid distribution,
and increased membrane permeability. These modifications
result in the formation of erythrocyte membrane channels
called ‘‘new permeability pathways’’ (NPPs), thus allowing
the selective entry of low molecular weight molecules to
the infected erythrocytes [22, 23]. In contrast, uninfected
erythrocyte membranes retain asymmetry, and phosphati-
dylserine is not presented at the external surface prior to a
pathological stimulus [6, 24, 25]. AMPs may also have an
indirect effect on malaria parasite survival. For example,
some synthetic peptides have been shown to kill intracel-
lular blood-stage forms of the malaria parasite [26],
whereas some studies have shown that AMPs can induce
Table 1 Effect of various concentrations of AMPs LR14 (antimi-
crobial peptides produced by L. plantarum strain LR/14) on the
hemolysis of infected (1 % parasitemia) and uninfected erythrocytes








100 0.9 ± 0.08 0
75 0.55 ± 0.03 0
50 0 0
25 0 0
Percentage hemolysis was calculated using the expression % hemo-
lysis = [A405nm (sample) - A405nm (negative control)]/A405nm (posi-
tive control)
AMPs antimicrobial peptides, RBCs red blood cells
Table 2 Acute AMPs LR14 (antimicrobial peptides produced by L. plantarum strain LR/14) administration to Wistar rats: mortality and






0 0/5 No treatment-related toxic signs and symptoms/mortality were observed
50 0/5 No treatment-related toxic signs and symptoms/mortality were observed
300 0/5 No treatment-related toxic signs and symptoms/mortality were observed
1,000 0/5 Shivering was noticed in all animals, which subsided within 24 h after the dose was given
2,000 5/5 Shivering, ruffled fur, and ataxia were noticed in all animals after dosing. All animals died within
4 h after dosing
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cells to undergo apoptosis [27]. Generally speaking, the
positively charged AMPs LR14 are expected to interact
electrostatically with the altered and negatively charged
plasma membrane of the infected erythrocytes, traversing
the membrane of the host and the parasite to reach its
target. It has been reported that the presence of non-polar
amino acid residues (providing lipophilic anchors) dra-
matically increases the biological activity, because of the
belief that these residues help in their penetration (disrup-
tion) through plasma membrane [6, 28, 29]. Therefore,
selective toxicity towards P. falciparum and negligible
hemolysis of uninfected erythrocytes are the major char-
acteristic properties of AMPs LR14. It should be admitted
here that the dose required to kill the parasite was much
more than that of chloroquine (the drug used against
malaria); nevertheless, AMPs LR14 still holds an important
place as it is produced from an L. plantarum strain that has
a GRAS (generally regarded as safe) status [11]. Therefore,
these peptides should not cause adverse effects on con-
sumption as therapeutics. Besides AMPs showing anti-
plasmodial activity, it has been reported that some AMPs
inhibit the growth of a protozoan parasite, Trypanosoma
brucei [30, 31].
The evaluation of AMPs through in vivo toxicity is con-
sidered an essential step before its consideration for thera-
peutic purposes [32]. Animal models have been frequently
used to evaluate the in vivo toxicity and to assess the effects
of bacteriocins in target organs [33]. The results of acute oral
toxicity tests of AMPs LR14 in Wistar rats determined that
the LD50 of AMPs LR14 lies between 1,000 and 2,000 mg/
kg. As reported by a number of investigators, the oral LD50 of
nisin in rats is[25 mg/kg [34], whereas it is 174 mg/kg in
mice [35, 36]. Also, studies on peptide P34 on BALB/c mice
identified the oral LD50 as[332.3 ± 0.76 mg/kg [37]. Most
pharmacokinetic studies/biodistribution suggest that oral
administration (parental administration) is highly recom-
mended versus other routes of administration [38]; being
soluble in water, AMPs LR14 were delivered in an oral form.
However, considering the therapeutic application of the
peptides, subcutaneous and intravenous administrations
need to be evaluated.
Histological studies indicated that AMPs LR14 at
1,000 mg/kg may result in minimal changes in the liver
and no observable changes in the kidney, reflecting its safe
use for in vivo administration as a therapeutic. In the liver
Table 3 Cumulative body weight of control and test rats after AMPs





Day 1 Day 2 Day 3
0 174 ± 5 181 ± 5 189 ± 5.7
50 173 ± 7.5 179 ± 8 186 ± 9
300 174 ± 1.5 181 ± 2.5 189 ± 3.6
1,000 165 ± 2.5 170 ± 3 177 ± 2.6
2,000 162 ± 2.5
Fig. 2 Histopathological observations in control and test rats
(administered with AMPs LR14-1,000 mg/kg). a Control kidney
(H&E stains 9100) showing normal renal parenchyma. b Control
kidney (H&E 9400) showing a glomerulus with normal size and
cellularity. Malpighian tubules are within normal limits. c Treated
kidney (AMPs LR14 1,000 mg/kg) (H&E 9100) showing normal
renal parenchyma. d Treated kidney (H&E 9400) showing a
glomerulus with normal size and cellularity. Tubules are within
normal limits. No pathological changes were observed. e Control liver
(H&E 9100) showing normal liver parenchyma. f Control liver (H&E
9400) showing a portal triad (arrow). g Treated liver (AMPs LR14
1,000 mg/kg) (H&E 9100) showing normal liver parenchyma.
h Treated liver (H&E 9400), where the portal area of the liver
shows mild inflammatory cell infiltration around the portal triad
(arrow). No other pathological changes is seen. AMPs antimicrobial
peptides, BD bile duct, CV central vein, G glomerulus, H&E
hematoxylin and eosin, PT portal triad, PV portal vein, T tubules
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of the nisin-treated animals, histological changes suggested
some hepatic degeneration [37]. Similarly, another study
showed that nisin A administered to rats at a 5 % dietary
level for 90 days did not cause any toxicological adverse
effect, although statistically significant differences were
observed at the tissue level [38]. Comparing these results,
AMPs LR14 seem to be a better candidate as they have a
higher LD50 than the other tested AMPs.
Moreover, AMPs LR14 failed to elicit an immunogenic
response as no antibodies were generated when a rabbit was
exposed to these peptides. These results are in accordance
with other bacteriocins/AMPs, where a lack of immunogenic
response in mice or rabbits has been reported. The antibodies
were produced only when these peptides were conjugated
with carrier proteins/adjuvants [37, 39, 40].
5 Conclusion
All of these results led us to conclude that AMPs LR14 have
potential for development of a new antiplasmodial com-
pound. Additionally, this investigation points out that AMPs
LR14 can be combined with various antimalarial drugs as a
combination therapy that may also delay or hamper the onset
of growing resistance to the already available drugs. Such
studies can provide an essential therapeutic value for clinical
studies against Plasmodium spp.This is a preliminary study
that provides important leads for conducting further studies
to prove AMPs LR14 as potent anti-malarial peptides. Also,
acute toxicity tests provide baseline information about the
non-toxic nature of the bioactive peptides.
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